Screener
Agios Pharmaceuticals AGIO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Agios Pharmaceuticals’s reported figures.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's EBITDA?
- Agios Pharmaceuticals (AGIO) reported EBITDA of -$109.2M in Q2 2026.
- How has Agios Pharmaceuticals's EBITDA changed year-over-year?
- Agios Pharmaceuticals's EBITDA increased by 13.2% year-over-year, from -$125.8M to -$109.2M.
- What is the long-term trend for Agios Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's EBITDA has grown at a 6.0% compound annual growth rate (CAGR), from -$369.18M to -$466.96M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Agios Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude